5 research outputs found
Recommended from our members
Bone Marrow-Derived Multipotent Stromal Cells Attenuate Inflammation in Obliterative Airway Disease in Mouse Tracheal Allografts
Obliterative bronchiolitis (OB) remains the most significant cause of death in long-term survival of lung transplantation. Using an established murine heterotopic tracheal allograft model, the effects of different routes of administration of bone marrow-derived multipotent stromal cells (MSCs) on the development of OB were evaluated. Tracheas from BALB/c mice were implanted into the subcutaneous tissue of major histocompatibility complex- (MHC-) disparate C57BL/6 mice. At the time of transplant, bone marrow-derived MSCs were administered either systemically or locally or via a combination of the two routes. The allografts were explanted at various time points after transplantation and were evaluated for epithelial integrity, inflammatory cell infiltration, fibrosis, and luminal obliteration. We found that the most effective route of bone marrow-derived MSC administration is the combination of systemic and local delivery. Treatment of recipient mice with MSCs suppressed neutrophil, macrophage, and T-cell infiltration and reduced fibrosis. These beneficial effects were observed despite lack of significant MSC epithelial engraftment or new epithelial cell generation. Our study suggests that optimal combination of systemic and local delivery of MSCs may ameliorate the development of obliterative airway disease through modulation of immune response
Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
There is a strong biologic rationale that poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors may benefit a broader range of metastatic breast cancer (MBC) patients than covered by current approvals, which require a germline BRCA1/2 sequence variant affecting function. We report a patient with germline/somatic BRCA1/2 wild-type MBC, who had a dramatic response to the PARP inhibitor olaparib of at least 8 months' duration. The patient is a 37-year-old woman with recurrent, hormone receptor-positive, HER2-negative MBC that had progressed despite hormonal therapy and palbociclib. Sensitivity to olaparib was likely conferred by a germline sequence variant affecting function in PALB2 (exon 1, c.18G>T, p.(=)). This case documenting activity of olaparib monotherapy in germline/somatic BRCA1/2 wild-type MBC illustrates that the clinical potential of PARP inhibition in MBC extends beyond currently approved indications to additional patients whose tumors have (epi)genetic changes affecting homologous recombination repair
sj-docx-1-tam-10.1177_17588359231200454 â Supplemental material for Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
Supplemental material, sj-docx-1-tam-10.1177_17588359231200454 for Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany by Mattea Reinisch, Simona Bruzas, Jennifer Spoenlein, Satyendra Shenoy, Alexander Traut, Hakima Harrach, Ouafaa Chiari, Efsthatia Cremer, Beyhan Ataseven, Lars Gubelt and Sherko Kuemmel in Therapeutic Advances in Medical Oncology</p
Prognostic and predictive impact of gene expression in nodeâpositive early breast cancer patients receiving doseâdense versus standardâdose adjuvant chemotherapy
The utility of multigene expression assays in advanced (â„â4 positive lymph nodes) early breast cancer (EBC) is limited. We conducted exploratory transcriptomic analysis of 758 genes (Breast Cancer 360 panel, nCounterÂź platform; NanoString) in primary tumor samples collected during a phase 3 trial comparing adjuvant taxaneâcontaining doseâdense chemotherapy (ddCTX) versus standardâdosed chemotherapy (stCTX) in resected EBC with â„â4 positive lymph nodes. Prognostic and predictive associations with diseaseâfree survival (DFS) and overall survival (OS) were evaluated by Cox regression with false discovery rate (FDR) adjustment. Data were available from tumor samples of 141/226 patients (median followâup: 14âyears). Several genes/signatures, including immune markers, showed prognostic relevance in unadjusted analyses. Of these, two remained significant after multiplicity adjustment: a positive effect on DFS of programmed cell death 1 ligandâ2 (PDâL2) in the ddCTX arm (univariate HR: 0.53, FDRâadjusted Pâ=â0.036) and a negative effect on OS of HER2âenriched (HER2âE) signature in the stCTX arm (univariate HR: 5.40, FDRâadjusted Pâ=â0.036). Predictive analyses showed greater DFS benefit of ddCTX in tumors with high antigen processing machinery (APM) expression (multivariate interaction Pâ=â0.024). Multigene expression assays have a prognostic and predictive potential in advanced EBC, and further investigation is warranted in order to identify candidates for deâescalated treatment. In addition, intrinsic subtype and immune gene expression have predictive potential